Y Intercept Hong Kong Ltd grew its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) by 79.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 828,879 shares of the company’s stock after acquiring an additional 366,713 shares during the quarter. Y Intercept Hong Kong Ltd owned 0.46% of Compass Therapeutics worth $4,385,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently bought and sold shares of CMPX. Flagship Harbor Advisors LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter valued at about $32,000. Russell Investments Group Ltd. boosted its holdings in Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after purchasing an additional 7,592 shares during the last quarter. Xponance LLC bought a new stake in Compass Therapeutics in the 4th quarter worth about $55,000. CIBC Bancorp USA Inc. bought a new stake in Compass Therapeutics in the 3rd quarter worth about $37,000. Finally, Creative Planning purchased a new stake in Compass Therapeutics in the 2nd quarter valued at about $30,000. 68.43% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages have recently weighed in on CMPX. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Monday, April 20th. Guggenheim reaffirmed a “buy” rating and set a $12.00 price target on shares of Compass Therapeutics in a research report on Tuesday, March 24th. HC Wainwright reiterated a “buy” rating and set a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 27th. Citigroup reissued a “market outperform” rating on shares of Compass Therapeutics in a research report on Thursday, June 4th. Finally, Raymond James Financial downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 28th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.25.
Compass Therapeutics Price Performance
Compass Therapeutics stock opened at $2.27 on Monday. Compass Therapeutics, Inc. has a twelve month low of $1.61 and a twelve month high of $6.88. The firm has a 50 day moving average price of $2.14 and a 200-day moving average price of $4.41. The company has a market capitalization of $408.80 million, a P/E ratio of -5.54 and a beta of 0.90.
Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). Equities analysts expect that Compass Therapeutics, Inc. will post -0.42 EPS for the current fiscal year.
Compass Therapeutics Company Profile
Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.
The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.
Featured Articles
- Five stocks we like better than Compass Therapeutics
- Visa’s Open USD Push Puts Circle’s Stablecoin Moat Under Pressure
- This Under-the-Radar Industrial Is Quietly Powering AI
- Why Microsoft Looks Like the Best Big Tech Trade for H2 2026
- Strategy’s Bitcoin Pivot Gives Investors a New Reason to Watch Preferred Shares
Want to see what other hedge funds are holding CMPX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report).
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-SHOGGOTH.png){kind=small}
